Immuno-oncology focusing on women’s cancers Technology Although cancer therapies have been developed that stimulate the immune system, these approaches have often proven ineffective because the cancers remain invisible to the immune system. […]
Technology CEL-SCI Corporation is a late-stage biopharmaceutical company developing products for life-threatening diseases (such as cancer and infectious diseases). Its lead pipeline product – Multikine investigational immunotherapy (Leukocyte Interleukin, Injection) is a […]
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on […]
Head & Neck Cancer Report Launched The first chapter of the Cancer Impact Guide includes an overall summary of the current approach to diagnosis and standard of care and profiles of companies. […]
Cible is a preclinical-stage cancer drug company that solves the major problems of traditional cancer therapy through the implementation of a smart drug platform. The first lead candidate, oxaliTEX, is found to […]
Tosk is a dynamic drug development company dedicated to alleviating the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients […]
TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead […]
OTraces has developed a disruptive technology using math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer diagnostics. By using these techniques to access the active proteins found in the […]
